The behavior of epididymis, processus vaginalis and testicular descent in cryptorchid boys treated with buserelin.
This randomized double-blind, placebo-controlled study was initiated to analyze the behavior of epididymis, processus vaginalis and testicular descent in cryptorchid boys treated with a low dose (20 micrograms) of a luteinizing hormone-releasing hormone analogue (Buserelin), administered daily, as a nasal spray, for a short period (28 days). Fifty-nine true cryptorchid boys were randomly assigned to 3 groups: buserelin treatment [22], surgical treatment [18] or placebo control group [19]. The 3 groups of patients were similar before treatment in regard to testicular position, chronological and bone age, height and weight, luteinizing hormone, follicle-stimulating hormone, testosterone, penile size and the volume of the contralateral descended testis. None of the patients had retractile testes. Buserelin significantly induced testicular descent compared to the boys treated with a placebo (P < 0.01). A normal epididymis was found more often in boys with successful descent (P < 0.003). A closed processus vaginalis was also more frequently observed in the group treated with buserelin than in surgically treated one (P < 0.05). In conclusion, buserelin was capable of inducing testicular descent besides provoking further development of the epididymis and closing the processus vaginalis.
Bica
D T
DT
Department of Pediatric Surgery, Federal University Children's Hospital, Rio de Janeiro, Brazil.
Hadziselimovic
F
F
D000281:Administration, Intranasal; D002064:Buserelin / Q000627:therapeutic use*; D002648:Child; D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D003456:Cryptorchidism / Q000188:drug therapy* / Q000601:surgery; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004822:Epididymis / Q000187:drug effects; D006801:Humans; D008297:Male; D010537:Peritoneum / Q000187:drug effects; D013737:Testis / Q000187:drug effects*
D006063:Chorionic Gonadotropin; D002064:Buserelin